WEBINAR - Employees & employers can both benefit from a cancer prevention and early detection strategy
24 October 2023
A 30-minute webinar for HR professionals and line managers, in partnership with Check4Cancer.
About this event
Despite the best efforts of the NHS, the combined pressure of a global pandemic and ongoing underfunding has meant that cancer waiting times are amongst the worst on record, with missed targets for referrals, diagnosis and treatment.*
For this webinar, we’re joined by Professor Gordon Wishart, Chief Medical Officer at Check4Cancer – one of Generali UK’s valued Wellbeing Investment Matching partners – who will talk about the current state of play and how employers can help:
- The current state of UK cancer services
- Why UK survival lags behind most Organisation for Economic Cooperation and Development (OECD) countries
- Cancer prevention through education & screening
- Cancer risk assessment & risk reduction
- Risk-stratified screening (focusing screening on those at highest risk – risk assessment & screening delivered by C4C).
This event has now concluded.
Professor Gordon Wishart MBChB MA (Cantab.) MD FRCS (Eng.) FRCS (Gen.)
Professor Gordon Wishart is the former Director of the Cambridge Breast Unit from 2005-2010, and current Visiting Professor of Cancer Surgery at Anglia Ruskin University since 2008. He has a strong track record in clinical research, with more than 100 peer-reviewed papers in scientific journals. In 2010 he led a team of clinicians and scientists that developed the PREDICT breast cancer treatment and survival model, now used worldwide.
Professor Wishart is also the founder, CEO & Chief Medical Officer of Cambridge-based Check4Cancer, a leading early cancer detection company. In 2016 Check4Cancer launched rapid access, streamlined and audited diagnostic pathways for breast and skin cancer to the insured and self-pay markets, leading to the award of “Diagnostic Provider of the Year” at the annual Health Investor Awards in 2018. Check4Cancer has recently developed cancer risk assessment and impact models that underpin risk-stratified cancer screening programmes, with education and behavioural change at the centre of a cancer prevention strategy, resulting in the 2022 Laing Buisson “Innovation in Health Tech” award for the MyCancerRisk programme.
Stay in touch
Keep informed about Generali products & services, events, wellbeing calendar updates and more.
Sign up and select your preferences using this link.